Alnylam Pharmaceuticals
ALNY
#634
Rank
NZ$57.07 B
Marketcap
$440.86
Share price
0.54%
Change (1 day)
80.73%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Alnylam Pharmaceuticals (ALNY) - Total debt

Total debt on the balance sheet as of December 2024 : NZ$2.27 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's total debt is NZ$2.27 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Alnylam Pharmaceuticals - Total debt on balance sheet (from 2003 to 2024)

Total debt by year

Year Total debt Change
2023-12-31NZ$2.06 B-0.73%
2022-12-31NZ$2.07 B42.38%
2021-12-31NZ$1.46 B102.2%
2020-12-31NZ$0.72 B60.12%
2019-12-31NZ$0.45 B908.67%
2018-12-31NZ$44.72 M5.88%
2017-12-31NZ$42.24 M-80.49%
2016-12-31NZ$0.21 B
2007-12-31NZ$8.82 M-31.97%
2006-12-31NZ$12.96 M19.86%
2005-12-31NZ$10.81 M7.21%
2004-12-31NZ$10.09 M252.89%
2003-12-31NZ$2.85 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
NZ$0.92 B-59.47%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$4.74 B 108.66%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$2.45 B 7.83%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$0.89 B-60.47%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$0.83 M-99.96%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$54.82 B 2,311.79%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
NZ$44.65 B 1,864.48%๐Ÿ‡ซ๐Ÿ‡ท France
NZ$31.70 B 1,294.93%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel